IE
VOR icon

Israel Englander’s Vor Biopharma VOR Stock Holding History

Israel Englander’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,500
Closed -$178K – 6503
2025
Q2 		$178K Buy
+5,500
New +$48.6K ﹤0.01% 5398

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Israel Englander's VOR Position: Q2 2026 in Review

Israel Englander increased its Vor Biopharma (VOR) stake by 66% in Q2 2026, buying an estimated $2.56M and bringing the position to 428,067 shares worth $7.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

Israel Englander first reported a position in VOR in Q2 2021 and has held it in 16 quarters since. 101 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Israel Englander held 428,067 shares of Vor Biopharma worth $7.88M as of Q2 2026.
  • Israel Englander bought 169,480 Vor Biopharma shares in Q2 2026, an estimated $2.56M.
  • Vor Biopharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2547 holding.
  • Israel Englander first reported a position in Vor Biopharma in Q2 2021 and has held it in 16 quarters since.
  • 101 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.